Insider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) CFO Sells 5,000 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CFO Nicole Labrosse sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $53.93, for a total transaction of $269,650.00. Following the transaction, the chief financial officer now owns 15,480 shares of the company’s stock, valued at $834,836.40. The transaction was disclosed in a filing with the SEC, which is available through this link.

Nicole Labrosse also recently made the following trade(s):

• On Thursday, June 27th, Nicole Labrosse sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $51.93, for a total transaction of $519,300.00.

Halozyme Therapeutics Stock Up 1.5 %

Shares of NASDAQ HALO opened at $55.97 on Friday. The firm has a market cap of $7.12 billion, a PE ratio of 23.23, a P/E/G ratio of 0.56 and a beta of 1.27. Halozyme Therapeutics, Inc. has a 12-month low of $32.83 and a 12-month high of $56.97. The company’s fifty day simple moving average is $49.81 and its 200 day simple moving average is $42.44. The company has a quick ratio of 5.36, a current ratio of 6.64 and a debt-to-equity ratio of 8.44.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.07. The business had revenue of $195.88 million for the quarter, compared to analyst estimates of $201.72 million. Halozyme Therapeutics had a net margin of 36.94% and a return on equity of 225.71%. As a group, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 3.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Rise Advisors LLC bought a new position in Halozyme Therapeutics during the first quarter worth $25,000. Whittier Trust Co. acquired a new position in Halozyme Therapeutics during the first quarter worth $27,000. GAMMA Investing LLC raised its holdings in Halozyme Therapeutics by 96.6% during the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 254 shares during the last quarter. Principal Securities Inc. acquired a new position in Halozyme Therapeutics during the fourth quarter worth $34,000. Finally, Fidelis Capital Partners LLC acquired a new position in Halozyme Therapeutics during the first quarter worth $52,000. 97.79% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on HALO shares. JMP Securities lowered their price objective on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating for the company in a research report on Wednesday, May 8th. Benchmark boosted their target price on shares of Halozyme Therapeutics from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. HC Wainwright reissued a “buy” rating and set a $65.00 target price on shares of Halozyme Therapeutics in a report on Tuesday, July 16th. Wells Fargo & Company boosted their target price on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the stock an “overweight” rating in a report on Friday, June 7th. Finally, Piper Sandler lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their target price for the stock from $48.00 to $51.00 in a report on Friday, June 7th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $58.38.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.